Velpatasvir-13C,d3

Velpatasvir-13C,d3

• UNSPSC Description: Velpatasvir-13C,d3 (GS-5816-13C,d3) is 13C and deuterium labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM[1][2][3].
• Target Antigen: Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Others
• Field of Research: Cancer;Infection;Inflammation/Immunology
• Smiles: O=C(OC)N[C@@H](C(C)C)C(N1[C@@H](C2=NC3=CC=C4C=C5C(OCC6=C5C=CC(C7=CNC([C@H]8N(C([C@H](NC(O[13C]([2H])([2H])[2H])=O)C9=CC=CC=C9)=O)C[C@@H](COC)C8)=N7)=C6)=CC4=C3N2)CC[C@@H]1C)=O
• Molecular Weight: 887.01
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported